EasySep™ Direct Human B-CLL Cell Isolation Kit_产品中心

细胞分选产品

EasySep™ Direct Human B-CLL Cell Isolation Kit

Immunomagnetic negative selection from whole blood kit

概要

技术资料

数据及文献

概要

This kit isolates untouched and highly purified B-CLL cells directly from human whole blood by fully immunomagnetic negative selection. The depletion cocktail in this kit does not contain antibodies against CD43, which can be expressed on malignant cells in chronic lymphocytic leukemia (CLL) samples.

This cell isolation kit targets non-B cells for removal based on specific surface antigens. Unwanted cells are labeled with antibodies and EasySep™ Direct RapidSpheres™, and separated using an EasySep™ magnet. Desired cells are simply collected into a new tube and can immediately be used in downstream applications such as nucleic acid extraction, flow cytometry or culture.

技术资料

Document Type	产品名称	Catalog #	Lot #	语言
Product Information Sheet	EasySep™ Direct Human B-CLL Cell Isolation Kit	19664	All	English
Safety Data Sheet 1	EasySep™ Direct Human B-CLL Cell Isolation Kit	19664	All	English
Safety Data Sheet 2	EasySep™ Direct Human B-CLL Cell Isolation Kit	19664	All	English

数据及文献

Data

$Starting with human whole blood from normal healthy donors, the typical B cell (CD3-CD19+) content of the non-lysed final isolated fraction is 87.0 ± 7.6% (gated on CD45) or 84.1 ± 11.7% (not gated on CD45)$

Figure 1. Typical EasySep™ Direct Human B-CLL Cell Isolation Profile

Starting with human whole blood from normal healthy donors, the typical B cell (CD3-CD19+) content of the non-lysed final isolated fraction is 87.0 ± 7.6% (gated on CD45) or 84.1 ± 11.7% (not gated on CD45). In the example above, the B cell (CD3-CD19+) content of the lysed whole blood start and non-lysed final isolated fraction is 4.3% and 88.0% (gated on CD45), respectively, or 4.3% and 86.2% (not gated on CD45), respectively. The starting frequency of B cells in the non-lysed whole blood start sample above is 0.004% (data not shown). The purity of isolated cells is typically higher when processing samples that have an elevated starting frequency of B cells (e.g. CLL samples).